Mona Parmar
About
Mona Parmar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Mona Parmar has authored 18 papers receiving a total of 92 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Mona Parmar's work include Ovarian cancer diagnosis and treatment (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Mona Parmar is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Mona Parmar collaborates with scholars based in United Kingdom, Australia and Canada. Mona Parmar's co-authors include Alison Turner, Udai Banerji, Emma Hall, Juanita Lopez, Johann S. de Bono, Nina Tunariu, Anna Minchom, S.J. Harris, Holly Tovey and Susana Banerjee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Mona Parmar
16 papers receiving 91 citations
Peers
Mona Parmar
Errin Samuëlsz United States
Francesca Pettinella United States
Alejandro Falcón Spain
Deukchae Na South Korea
Deyaa Adib United States
Ramona Crescenzo United States
Eugenia Ortega Spain
Alyssa Parker United States
Marcin Dzienis Australia
Emmanuel S. Antonarakis United States
Citations per year, relative to Mona Parmar Mona Parmar (= 1×)
peers
Errin Samuëlsz
Countries citing papers authored by Mona Parmar
Since
Specialization
Citations
This map shows the geographic impact of Mona Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Parmar more than expected).
Fields of papers citing papers by Mona Parmar
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mona Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Parmar. The network helps show where Mona Parmar may publish in the future.
Co-authorship network of co-authors of Mona Parmar
This figure shows the co-authorship network connecting the top 25 collaborators of Mona Parmar. A scholar is included among the top collaborators of Mona Parmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Parmar. Mona Parmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Welsh, Liam, Anna Zachariou, Mona Parmar, et al.. (2023). Abstract CT093: Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787). Cancer Research. 83(8_Supplement). CT093–CT093.
2.
Rodney, Simon, Lisa Pickard, Mona Parmar, et al.. (2023). Abstract 3461: Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer. Cancer Research. 83(7_Supplement). 3461–3461.
3.
Pickard, Lisa, Stephanie Lustgarten, Jonathan A. Pachter, et al.. (2022). Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response. Cancer Research. 82(12_Supplement). 3476–3476.
4.
Minchom, Anna, Christina Guo, Nina Tunariu, et al.. (2022). Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.. Journal of Clinical Oncology. 40(16_suppl). 9018–9018.
5.
Banerjee, Susana, João Paulo da Silveira Nogueira Lima, Matthew Krebs, et al.. (2021). 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology. 32. S728–S728.
6.
Krebs, Matthew, Jenny King, Joseph Kitchin, et al.. (2021). Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. Cancer Research. 81(13_Supplement). CT019–CT019.
7.
Banerjee, Susana, Alvaro Ingles Garces, Andrea Biondo, et al.. (2020). A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.. Journal of Clinical Oncology. 38(15_suppl). 6043–6043.
8.
Lopez, Juanita, Malaka Ameratunga, Anna Minchom, et al.. (2019). PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. Journal of Clinical Oncology. 37(15_suppl). 3087–3087.
9.
Pascual, Javier, Iain R. Macpherson, Anne Armstrong, et al.. (2019). PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.. Journal of Clinical Oncology. 37(15_suppl). 1051–1051.
10.
Sriskandarajah, Priya, Kevin Boyd, Wen Xu, et al.. (2018). Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood. 132(Supplement 1). 3237–3237.
11.
Krebs, Matthew, James Spicer, Nicola Steele, et al.. (2017). P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. Journal of Thoracic Oncology. 12(1). S1272–S1273.
12.
Chénard-Poirier, Maxime, Martin Kaiser, Kevin Boyd, et al.. (2017). Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. Journal of Clinical Oncology. 35(15_suppl). 2506–2506.
13.
Lim, Joline S.J., Uzma Asghar, Nikolaos Diamantis, et al.. (2017). A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. Journal of Clinical Oncology. 35(15_suppl). 2573–2573.
14.
Banerji, Udai, Alvaro Ingles Garces, Vasiliki Michalarea, et al.. (2017). An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2503–2503.
15.
Harris, S.J., Maria J. de Miguel, Mona Parmar, et al.. (2016). Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.. Journal of Clinical Oncology. 34(15_suppl). 2582–2582.
16.
Michalarea, Vasiliki, José Ramón Antúnez López, David Lorente, et al.. (2015). 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). European Journal of Cancer. 51. S68–S68.
17.
Basu, Bristi, Mona Parmar, Andrea Turner, et al.. (2014). Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013). Annals of Oncology. 25. iv156–iv156.
18.
Cooper, Michael R., Karen Poole, David Cameron, et al.. (2012). Five fold increase in recruitment of cancer patients to NIHR Cancer Research Network portfolio studies between 2001-2011. View.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Errin Samuëlsz Breakdown of academic impact, for papers by Francesca Pettinella Breakdown of academic impact, for papers by Alejandro Falcón Breakdown of academic impact, for papers by Deukchae Na Breakdown of academic impact, for papers by Deyaa Adib Breakdown of academic impact, for papers by Ramona Crescenzo Breakdown of academic impact, for papers by Eugenia Ortega Breakdown of academic impact, for papers by Alyssa Parker Breakdown of academic impact, for papers by Marcin Dzienis Breakdown of academic impact, for papers by Emmanuel S. Antonarakis